|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Soto-Perez-de-Celis E and Chavarri-Guerra
Y: National and regional breast cancer incidence and mortality
trends in Mexico 2001–2011: Analysis of a population-based
database. Cancer Epidemiol. 41:24–33. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Spitale A, Mazzola P, Soldini D,
Mazzucchelli L and Bordoni A: Breast cancer classification
according to immunohistochemical markers: Clinicopathologic
features and short-term survival analysis in a population-based
study from the South of Switzerland. Ann Oncol. 20:628–635. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sotiriou C and Pusztai L: Gene-expression
signatures in breast cancer. N Engl J Med. 360:790–800. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Weigelt B, Baehner FL and Reis-Filho JS:
The contribution of gene expression profiling to breast cancer
classification, prognostication and prediction: A retrospective of
the last decade. J Pathol. 220:263–280. 2010.PubMed/NCBI
|
|
6
|
Dietze EC, Sistrunk C, Miranda-Carboni G,
O'Regan R and Seewaldt VL: Triple-negative breast cancer in
African-American women: Disparities versus biology. Nat Rev Cancer.
15:248–254. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Carey LA, Dees EC, Sawyer L, Gatti L,
Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML and Perou
CM: The triple negative paradox: Primary tumor chemosensitivity of
breast cancer subtypes. Clin Cancer Res. 13:2329–2334. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liedtke C, Mazouni C, Hess KR, André F,
Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B,
Green M, et al: Response to neoadjuvant therapy and long-term
survival in patients with triple-negative breast cancer. J Clin
Oncol. 26:1275–1281. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Foulkes WD, Smith IE and Reis-Filho JS:
Triple-negative breast cancer. N Engl J Med. 363:1938–1948. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shah SP, Roth A, Goya R, Oloumi A, Ha G,
Zhao Y, Turashvili G, Ding J, Tse K, Haffari G, et al: The clonal
and mutational evolution spectrum of primary triple-negative breast
cancers. Nature. 486:395–399. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cancer Genome Atlas Network: Comprehensive
molecular portraits of human breast tumours. Nature. 490:61–70.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Metzker ML: Sequencing technologies-the
next generation. Nat Rev Genet. 11:31–46. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kan Z, Jaiswal BS, Stinson J, Janakiraman
V, Bhatt D, Stern HM, Yue P, Haverty PM, Bourgon R, Zheng J, et al:
Diverse somatic mutation patterns and pathway alterations in human
cancers. Nature. 466:869–873. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wagle N, Emery C, Berger MF, Davis MJ,
Sawyer A, Pochanard P, Kehoe SM, Johannessen CM, Macconaill LE,
Hahn WC, et al: Dissecting therapeutic resistance to RAF inhibition
in melanoma by tumor genomic profiling. J Clin Oncol. 29:3085–3096.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hrstka R, Coates PJ and Vojtesek B:
Polymorphisms in p53 and the p53 pathway: Roles in cancer
susceptibility and response to treatment. J Cell Mol Med.
13:440–453. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mroz EA, Tward AD, Pickering CR, Myers JN,
Ferris RL and Rocco JW: High intratumor genetic heterogeneity is
related to worse outcome in patients with head and neck squamous
cell carcinoma. Cancer. 119:3034–3042. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gerlinger M, Rowan AJ, Horswell S, Math M,
Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N,
Stewart A, et al: Intratumor heterogeneity and branched evolution
revealed by multiregion sequencing. N Engl J Med. 366:883–892.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Macdonald SM, Harris EE, Arthur DW, Bailey
L, Bellon JR, Carey L, Goyal S, Halyard MY, Horst KC, Moran MS and
Haffty BG: ACR appropriateness criteria® locally
advanced breast cancer. Breast J. 17:579–585. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Simen BB, Yin L, Goswami CP, Davis KO,
Bajaj R, Gong JZ, Peiper SC, Johnson ES and Wang ZX: Validation of
a next-generation-sequencing cancer panel for use in the clinical
laboratory. Arch Pathol Lab Med. 139:508–517. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Oren M and Rotter V: Mutant p53
gain-of-function in cancer. Cold Spring Harb Perspect Biol.
2:a0011072010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Muller PA and Vousden KH: p53 mutations in
cancer. Nat Cell Biol. 15:2–8. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Weisman PS, Ng CK, Brogi E, Eisenberg RE,
Won HH, Piscuoglio S, De Filippo MR, Ioris R, Akram M, Norton L, et
al: Genetic alterations of triple negative breast cancer by
targeted next-generation sequencing and correlation with tumor
morphology. Mod Pathol. 29:476–488. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xu H and el-Gewely MR: P53-responsive
genes and the potential for cancer diagnostics and therapeutics
development. Biotechnol Annu Rev. 7:131–164. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Levine AJ: p53, the cellular gatekeeper
for growth and division. Cell. 88:323–331. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wallace-Brodeur RR and Lowe SW: Clinical
implications of p53 mutations. Cell Mol Life Sci. 55:64–75. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jones JS, Chi X, Gu X, Lynch PM, Amos CI
and Frazier ML: p53 polymorphism and age of onset of hereditary
nonpolyposis colorectal cancer in a Caucasian population. Clin
Cancer Res. 10:5845–5849. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Thomas M, Kalita A, Labrecque S, Pim D,
Banks L and Matlashewski G: Two polymorphic variants of wild-type
p53 differ biochemically and biologically. Mol Cell Biol.
19:1092–1100. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Dumont P, Leu JI, Della Pietra AC III,
George DL and Murphy M: The codon 72 polymorphic variants of p53
have markedly different apoptotic potential. Nat Genet. 33:357–365.
2003. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Soleimani A, Rahmani Y, Farshchian N,
Delpisheh A, Khassi K, Shahmohammadi A and Amirifard N: The
evaluation of p53 polymorphism at codon 72 and association with
breast cancer in iran: A systematic review and meta-analysis. J
Cancer Prev. 21:288–293. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bansal A, Das P, Kannan S, Mahantshetty U
and Mulherkar R: Effect of p53 codon 72 polymorphism on the
survival outcome in advanced stage cervical cancer patients in
India. Indian J Med Res. 144:359–365. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bressac B, Kew M, Wands J and Ozturk M:
Selective G to T mutations of p53 gene in hepatocellular carcinoma
from southern Africa. Nature. 350:429–431. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Smith-Sørensen B, Gebhardt MC, Kloen P,
McIntyre J, Aguilar F, Cerutti P and Børresen AL: Screening for
TP53 mutations in osteosarcomas using constant denaturant gel
electrophoresis (CDGE). Hum Mutat. 2:274–285. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Green RC, Berg JS, Grody WW, Kalia SS,
Korf BR, Martin CL, McGuire AL, Nussbaum RL, O'Daniel JM, Ormond
KE, et al: CORRIGENDUM: ACMG recommendations for reporting of
incidental findings in clinical exome and genome sequencing. Genet
Med. 19:6062017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Silwal-Pandit L, Vollan HK, Chin SF, Rueda
OM, McKinney S, Osako T, Quigley DA, Kristensen VN, Aparicio S,
Børresen-Dale AL, et al: TP53 mutation spectrum in breast cancer is
subtype specific and has distinct prognostic relevance. Clin Cancer
Res. 20:3569–3580. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Volinia S, Hiles I, Ormondroyd E, Nizetic
D, Antonacci R, Rocchi M and Waterfield MD: Molecular cloning, cDNA
sequence, and chromosomal localization of the human
phosphatidylinositol 3-kinase p110 alpha (PIK3CA) gene. Genomics.
24:472–477. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Katso R, Okkenhaug K, Ahmadi K, White S,
Timms J and Waterfield MD: Cellular function of phosphoinositide
3-kinases: Implications for development, homeostasis, and cancer.
Annu Rev Cell Dev Biol. 17:615–675. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Karakas B, Bachman KE and Park BH:
Mutation of the PIK3CA oncogene in human cancers. Br J Cancer.
94:455–459. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Cancer Genome Atlas Network. Comprehensive
molecular portraits of human breast tumours. Nature. 490:61–70.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Samuels Y, Wang Z, Bardelli A, Silliman N,
Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, et al:
High frequency of mutations of the PIK3CA gene in human cancers.
Science. 304:5542004. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lips EH, Michaut M, Hoogstraat M, Mulder
L, Besselink NJ, Koudijs MJ, Cuppen E, Voest EE, Bernards R,
Nederlof PM, et al: Next generation sequencing of triple negative
breast cancer to find predictors for chemotherapy response. Breast
Cancer Res. 17:1342015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Vaca-Paniagua F, Alvarez-Gomez RM,
Maldonado-Martinez HA, Pérez-Plasencia C, Fragoso-Ontiveros V,
Lasa-Gonsebatt F, Herrera LA, Cantú D, Bargallo-Rocha E, Mohar A,
et al: Revealing the molecular portrait of triple negative breast
tumors in an understudied population through omics analysis of
formalin-fixed and paraffin-embedded tissues. PLoS One.
10:e01267622015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Uras IZ, Walter GJ, Scheicher R, Bellutti
F, Prchal-Murphy M, Tigan AS, Valent P, Heidel FH, Kubicek S,
Scholl C, et al: Palbociclib treatment of FLT3-ITD+ AML cells
uncovers a kinase-dependent transcriptional regulation of FLT3 and
PIM1 by CDK6. Blood. 127:2890–2902. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Adamia S, Bar-Natan M, Haibe-Kains B,
Pilarski PM, Bach C, Pevzner S, Calimeri T, Avet-Loiseau H, Lode L,
Verselis S, et al: NOTCH2 and FLT3 gene mis-splicings are common
events in patients with acute myeloid leukemia (AML): New potential
targets in AML. Blood. 123:2816–2825. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Costa RLB, Han HS and Gradishar WJ:
Targeting the PI3K/AKT/mTOR pathway in triple-negative breast
cancer: A review. Breast Cancer Res Treat. 169:397–406. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Parrales A and Iwakuma T: Targeting
oncogenic mutant p53 for cancer therapy. Front Oncol. 5:2882015.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Synnott NC, Murray A, McGowan PM, Kiely M,
Kiely PA, O'Donovan N, O'Connor DP, Gallagher WM, Crown J and Duffy
MJ: Mutant p53: A novel target for the treatment of patients with
triple-negative breast cancer? Int J Cancer. 140:234–246. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Stone RM, Mandrekar SJ, Sanford BL,
Laumann K, Geyer S, Bloomfield CD, Thiede C, Prior TW, Döhner K,
Marcucci G, et al: Midostaurin plus chemotherapy for acute myeloid
leukemia with a FLT3 mutation. N Engl J Med. 377:454–464. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Bautista RR, Gómez AO, Miranda AH, Dehesa
AZ, Villarreal-Garza C, Ávila-Moreno F and Arrieta O: Correction
to: Long non-coding RNAs: Implications in targeted diagnoses,
prognosis, and improved therapeutic strategies in human non- and
triple-negative breast cancer. Clin Epigenetics. 10:1062018.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Nik-Zainal S, Van Loo P, Wedge DC,
Alexandrov LB, Greenman CD, Lau KW, Raine K, Jones D, Marshall J,
Ramakrishna M, et al: The life history of 21 breast cancers. Cell.
149:994–1007. 2012. View Article : Google Scholar : PubMed/NCBI
|
